Activity of Cefiderocol and Comparators against Isolates from Cancer Patients

Cefiderocol inhibited 97.5% of 478 Gram-negative isolates from cancer patients at ≤4 mg/liter. It had potent activity against extended-spectrum β-lactamase-positive Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae (CRE), and nonfermenting Gram-negative bacilli, including Pseudomonas aerug...

Descripción completa

Detalles Bibliográficos
Autores principales: Rolston, Kenneth V. I., Gerges, Baghat, Shelburne, Samuel, Aitken, Samuel L., Raad, Issam, Prince, Randall A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Susceptibility
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179642/
https://www.ncbi.nlm.nih.gov/pubmed/32071053
http://dx.doi.org/10.1128/AAC.01955-19
_version_ 1783525679624617984
author Rolston, Kenneth V. I.
Gerges, Baghat
Shelburne, Samuel
Aitken, Samuel L.
Raad, Issam
Prince, Randall A.
author_facet Rolston, Kenneth V. I.
Gerges, Baghat
Shelburne, Samuel
Aitken, Samuel L.
Raad, Issam
Prince, Randall A.
author_sort Rolston, Kenneth V. I.
collection PubMed
description Cefiderocol inhibited 97.5% of 478 Gram-negative isolates from cancer patients at ≤4 mg/liter. It had potent activity against extended-spectrum β-lactamase-positive Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae (CRE), and nonfermenting Gram-negative bacilli, including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Acinetobacter species isolates. Amikacin, ceftazidime-avibactam, and meropenem had appreciable activity against non-CRE Enterobacteriaceae. No comparators were active against multidrug-resistant P. aeruginosa isolates. Only trimethoprim-sulfamethoxazole had appreciable activity against S. maltophilia isolates. Overall, cefiderocol was associated with the lowest level of resistance.
format Online
Article
Text
id pubmed-7179642
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Society for Microbiology
record_format MEDLINE/PubMed
spelling pubmed-71796422020-04-27 Activity of Cefiderocol and Comparators against Isolates from Cancer Patients Rolston, Kenneth V. I. Gerges, Baghat Shelburne, Samuel Aitken, Samuel L. Raad, Issam Prince, Randall A. Antimicrob Agents Chemother Susceptibility Cefiderocol inhibited 97.5% of 478 Gram-negative isolates from cancer patients at ≤4 mg/liter. It had potent activity against extended-spectrum β-lactamase-positive Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae (CRE), and nonfermenting Gram-negative bacilli, including Pseudomonas aeruginosa, Stenotrophomonas maltophilia, and Acinetobacter species isolates. Amikacin, ceftazidime-avibactam, and meropenem had appreciable activity against non-CRE Enterobacteriaceae. No comparators were active against multidrug-resistant P. aeruginosa isolates. Only trimethoprim-sulfamethoxazole had appreciable activity against S. maltophilia isolates. Overall, cefiderocol was associated with the lowest level of resistance. American Society for Microbiology 2020-04-21 /pmc/articles/PMC7179642/ /pubmed/32071053 http://dx.doi.org/10.1128/AAC.01955-19 Text en Copyright © 2020 Rolston et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Susceptibility
Rolston, Kenneth V. I.
Gerges, Baghat
Shelburne, Samuel
Aitken, Samuel L.
Raad, Issam
Prince, Randall A.
Activity of Cefiderocol and Comparators against Isolates from Cancer Patients
title Activity of Cefiderocol and Comparators against Isolates from Cancer Patients
title_full Activity of Cefiderocol and Comparators against Isolates from Cancer Patients
title_fullStr Activity of Cefiderocol and Comparators against Isolates from Cancer Patients
title_full_unstemmed Activity of Cefiderocol and Comparators against Isolates from Cancer Patients
title_short Activity of Cefiderocol and Comparators against Isolates from Cancer Patients
title_sort activity of cefiderocol and comparators against isolates from cancer patients
topic Susceptibility
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7179642/
https://www.ncbi.nlm.nih.gov/pubmed/32071053
http://dx.doi.org/10.1128/AAC.01955-19
work_keys_str_mv AT rolstonkennethvi activityofcefiderocolandcomparatorsagainstisolatesfromcancerpatients
AT gergesbaghat activityofcefiderocolandcomparatorsagainstisolatesfromcancerpatients
AT shelburnesamuel activityofcefiderocolandcomparatorsagainstisolatesfromcancerpatients
AT aitkensamuell activityofcefiderocolandcomparatorsagainstisolatesfromcancerpatients
AT raadissam activityofcefiderocolandcomparatorsagainstisolatesfromcancerpatients
AT princerandalla activityofcefiderocolandcomparatorsagainstisolatesfromcancerpatients

Ejemplares similares